市場調查報告書
商品編碼
1267456
自動注射器市場——按類型、給藥途徑、療法、最終用途、全球預測,2023-2032 年Autoinjectors Market - By Type, By Route of Administration, By Therapy,, By End-use & Global Forecast, 2023 - 2032 |
全球自動注射器市場預計到 2032 年將呈指數增長,這是由於慢性病的增加導致對靶向治療的需求不斷增長。
此外,新型靶向藥物的推出和藥物開發投資有望推動自動注射器市場的增長。
此外,對自行服用藥物的日益偏愛將推動未來幾年的市場需求。 此外,減少大型生物製劑產品組合中使用的設計變更的時間、風險和成本的需求日益增長,預計將推動產品在全球範圍內的採用。
全球自動注射器行業的主要參與者繼續採取戰略舉措,例如併購、合作夥伴關係以及引入帶有一次性盒和電子驅動器的可重複使用自動注射器。 這些可重複使用的自動注射器包含預填充注射器,在最大限度地使用新藥的同時提供針頭安全性。 這種新興市場的發展正在推動更多患者使用自動注射器進行自我治療,進一步促進市場擴張。
總體而言,全球自動注射器市場在類型、給藥途徑、治療、最終用途和區域方面存在分歧。
按類型劃分,預計到 2022 年一次性用品的收入份額將超過 370 億美元,並在 2032 年之前實現顯著增長。 這種增長可歸因於一次性自動注射器提供的卓越功能,例如以患者為中心和支持完整藥物輸注的易用性。
按給藥途徑,肌肉注射器預計會顯著增長,因為它們用於過敏反應和過敏反應。 此外,由於它在緊急情況下發揮重要作用,因此有望擴大該領域。
基於治療,糖尿病細分市場預計將在 2022 年佔據超過 23% 的市場份額,並在 2032 年之前呈指數增長。 這種增長是由於糖尿病患者人數的增加和相關費用的增加。 世界衛生組織估計約有 4.22 億人患有糖尿病。
在最終用途方面,由於自動注射器提供的好處(例如管理過敏反應、糖尿病、急性發作、焦慮等),預計從 2023 年到 2032 年家庭護理環境部分將顯著增長。 此外,該產品的易用性、劑量控制和自我管理等特點有望在未來支持細分市場擴張。
按地區劃分,預計歐洲自動注射器市場在 2023 年至 2032 年期間的市場份額將超過 20%。 醫療器械行業的興起、監管框架的變化以及臨床試驗/證據的透明度是估計刺激歐洲自動注射器行業增長的主要因素。
Global Autoinjectors Market is slated to grow exponentially by 2032, owing to the rising demand for targeted therapies, in light of the growing prevalence of chronic diseases. In addition, introduction to novel targeted medicines and investments in drug development is slated to drive the growth of the autoinjectors market.
Besides, the rising preference for self-administration medication would propel the market demand in the ensuing years. Moreover, the increasing requirement to reduce the time and risk and expense of modifying designs that could be used across large biologic pharmaceutical portfolios are anticipated to foster the product adoption worldwide.
The key players in the global autoinjector industry are continuously incorporating strategic initiatives such as mergers and acquisitions, partnerships, and introducing reusable autoinjectors with disposable cassettes and electronic drive units. These reusable autoinjectors contain prefilled syringes and provide needle safety while maximizing the use of novel drugs. Such developments encourage more patients to use autoinjectors for self-administered medications, further augmenting market expansion.
Overall, the global autoinjectors market is bifurcated in terms of type, route of administration, therapy, end-use, and region.
Considering the type, the disposables segment held over USD 37 billion revenue share in 2022 and is slated to demonstrate massive growth through 2032. The growth can be attributed to the exceptional features offered by disposable autoinjectors, such as being patient-centric and easy operability to support the complete injection of medication.
By route of administration, the intramuscular autoinjectors segment is slated to grow considerably owing to its use for anaphylaxis and allergic reactions. In addition, these autoinjectors play a key role during an emergency, which will further support the segmental expansion.
Based on therapy, the diabetes segment held more than 23% market share in 2022 and is expected to grow exponentially through 2032. The growth can be credited to the rising cases and subsequent increase in expenses of diabetes. As per WHO estimates, approximately 422 million people suffer from diabetes.
By end-use, the homecare settings segment is depicted to grow notably during 2023-2032, owing to the benefits offered by autoinjectors, including managing anaphylaxis, diabetes, acute seizures, anxiety, and others. In addition, the product's capabilities, such as being easy usage, controlled dosage, and self-administrability, are further expected to support the segmental expansion in the future.
Regionally, the Europe global autoinjectors market is slated to exhibit over 20% market share between 2023-2032. The rising medical device industry, changes in the regulatory framework and transparency in the clinical trials/evidence are some key factors that are estimated to stimulate the Europe autoinjector industry growth.